AllSight
Companies · ANRO · Pharmaceutical Preparations

Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience, Inc. (ANRO) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Alto Neuroscience, Inc. (ANRO) stock — financials & valuation

Key numbers for Alto Neuroscience, Inc. (ANRO): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 40/100 — a percentile rank of Alto Neuroscience, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.

Market cap$993.2M
EV / EBITDA-8.8×
Return on equity-38.4%
ROIC1513.6%
Debt / equity0.1×
Dividend yield0.0%

Independent of the events above — derived from Alto Neuroscience, Inc.’s own financial statements and shown as context, never as advice.

Aug 27, 2026CFO elevated
Alto Neuroscience elevates CFO to president with a $6M retention package
Aug 12, 2026Beat
The EPS beat is small; the bigger story is a much broader ALTO-207 bet
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact